UEG 2023
Anti-TL1A: on the way to precision medicine?
high5immunology.tv | IBD | UEG Week 2023
ARTEMIS-UC, ARTEMIS-UC
UEG 2023
Anti-TL1A: on the way to precision medicine?
DIVERSITY1, U-ENDURE
UEG 2023
Do different JAKies have different profiles?
SELECTION, U-ACTIVATE
UEG 2023
Benefit of JAKies in ulcerative colitis
SEQUENCE
UEG 2023
The place of IL-23 blockers in crohn's disease
ARTEMIS-UC
UEG 2023
New kids on the block - next generation therapeutics
QUASAR, LUCENT-1/2, INSPIRE
UEG 2023
Is IL-23 blockade breaking the ceiling in UC?
True North, ELEVATE UC 12 & 52
UEG 2023
Key topic S1P-modulation
UEG 2023
Small molecules in IBD
SEQUENCE, INSPIRE
UEG 2023
A lot of noise about IL-23 blockers - 2
UEG 2023
News on IBD therapy!
QUASAR
UEG 2023
Guselkumab readily controls symptoms in patients…
QUASAR
UEG 2023
A lot of noise about IL-23 blockers - 1
DIVERSITY1, U-ENDURE
UEG 2023
Update on JAKies
QUASAR, SEQUENCE, INSPIRE
UEG 2023
Viel Wirbel um die Interleukin-23-Blockade
DIVERSITY1, U-ENDURE
UEG 2023
Update zu JAK-Inhibitoren
UEG 2023
Novità nelle terapie per le IBD!
True North, ELEVATE UC 12 & 52
UEG 2023
S1P-Modulatoren im Fokus
UEG 2023
Small molecules nelle IBD
QUASAR
UEG 2023
Rapido controllo dei sintomi nei pazienti affetti da…
OL maintenance Phase 2b
UEG 2023
Long-term efficacy of obefazimod in UC
SEQUENCE
UEG 2023
Risankizumab vs. ustekinumab in CD: The SEQUENCE trial
SEQUENCE
UEG 2023
Head-to-head efficacy comparison of risankizumab vs…
LUCENT-1/2
UEG 2023
Mirikizumab reaches similar therapeutic outcomes in UC…
DIVERSITY1
UEG 2023
Phase III results of filgotinib in CD
UEG 2023
High IL23 expression at baseline is predictive of…
SEQUENCE
UEG 2023
First positive head-to-head trial in CD
UEG 2023
Ustekinumab vs. adamlimumab for prevention of early…
SEQUENCE
UEG 2023
Comparazione testa a testa di Risankizumab e…
UEG 2023
Elevati livelli basali di IL23 predicono la remissione…
LUCENT-1/2
UEG 2023
Mirikizumab resulta efficace in RCU a prescindere dalla…
UEG 2023
Ustekinumab vs. adalimumab για την πρόληψη της πρώιμης…
LUCENT-1/2/3
UEG 2023
Longterm endohistological response induced by…
ARTEMIS-UC
UEG 2023
PRA023 - a new anti-TL1A antibody in moderate to severe…
INSPIRE
UEG 2023
Risankizumab in UC
ELEVATE UC 12 & 52
UEG 2023
Disease clearance induced by etrasimod and relationship…
True North
UEG 2023
Disease severity affects response in ozanimod treated…
ELEVATE UC 12 & 52
UEG 2023
Fast-acting etrasimod in UC
INSPIRE
UEG 2023
Another p19 antibody in UC
Lucent-1/2
UEG 2023
Mirikizumab in moderate to severe UC
ARTEMIS-UC
UEG 2023
PRA023 - un nuovo anticorpo anti-TL1A nella colite…
OL maintenance Phase 2b
UEG 2023
Lange termijn efficaciteit van Obefazimod UC
Lucent-1/3
UEG 2023
Mirikizumab nella colite ulcerosa da moderata a grave
DIVERSITY1
UEG 2023
Fase III resultaten met filgotinib in CD
True North, ELEVATE UC 12 & 52
UEG 2023
S1P modulation: ozanimod vs. etrasimod
POWER
UEG 2023
Efficacy and safety of switching iv vs. sc
VARSITY
UEG 2023
Combined endpoints - composition and implementation in…
PORCSE, SPICY TRIAL, KoCoRICCO
UEG 2023
How to prevent post-operative recurrence in CD?
VARSITY
UEG 2023
The quest for perfect predictors of response - AI…
CURE GETECCU (EXIT)
UEG 2023
Can we stop biologics?
UEG 2023
Navigating in the therapeutic IBD landscape
UEG 2023
To switch or not to switch in IBD - new real-life data…
UEG 2023
Infliximab sc application associated with better…
GETECCU (EXIT)
UEG 2023
More evidence that anti TNF-withdrawel increases…
UEG 2023
Navigeren in het therapeutisch landschap in IBD
UEG 2023
Infliximab sc führt zu besseren Langzeitergebnissen
UEG 2023
Konwersja do terapii podskórnej NZJ - nowe dane typu…
CURE
UEG 2023
Did GETAID close the window of opportunity?
KoCoRICCO, SPICY TRIAL
UEG 2023
Surgical news: prevention of post-operative recurrence…
PORCSE
UEG 2023
Postoperative recurrence in Crohn's disease after…
PORCSE
UEG 2023
Medical news: Which treatment and when?
SEQUENCE
UEG 2023
SEQUENCE study
CURE
UEG 2023
Stopping adalimumab in early CD?
KoCoRICCO, SPICY TRIAL
UEG 2023
Nouveauté sur la chirurgie: Prévention de la récidive…
PORCSE
UEG 2023
Actualités médicales: Quel traitement et quand?
CURE
UEG 2023
Peut-on arrêter l'adalimumab dans la maladie de Crohn…
CURE
UEG 2023
Hat GETAID das "Window of opportunity" geschlossen?
SEQUENCE
UEG 2023
SEQUENCE Studie
PORCSE
UEG 2023
Nawroty pooperacyjne u pacjentów z chorobą…
ARTEMIS-UC
UEG 2023
The anti TL1A/Dx-toolbox package: Are we entering…
UEG 2023
Which maintenance therapy in AS-CU is responding to…
UEG 2023
Quel traitement d'entretien dans l'AS-CU répondant aux…
ARTEMIS-UC
UEG 2023
Anti-TL1A im Paket mit der Dx-Toolbox - Einstieg in die…
VARSITY
UEG 2023
Comprehensive disease control - a new currency
VARSITY
UEG 2023
Comprehensive disease control - eine neue Währung
LUCENT-1/2, QUASAR, TORUS
UEG 2023
What do we know about multi-failures?
OCTAV,E U-ACTIVATE, DIVERSITY1, SELECTION
UEG 2023
New safety signals on JAKies?
ELEVATE UC 12 & 52
UEG 2023
S1P modulation: effective and safe?
ADVANCE, MOTIVATE, FORTIFY
UEG 2023
Is risankinumab effective for EIMs of IBD?
UEG 2023
Do JAK inhibitors cause acne?
GETECCU (EXIT)
UEG 2023
Is it feasible to stop effective anti-TNF therapy in…
ADVANCE/MOTIVATE post-hoc
UEG 2023
Effective control of EIMs in CD patients treated with…
GETECCU (EXIT)
UEG 2023
Czy możemy bezpiecznie przerwać skuteczną terapię…
UEG 2023
Προκαλούν οι αναστολείς των JAK ακμή;
ADVANCE, MOTIVATE, FORTIFY
UEG 2023
Είναι το risankisumab αποτελεσματικό για τη θεραπεία…
ADVANCE/MOTIVATE post-hoc
UEG 2023
Efficace controllo delle MEI in pazienti affetti da MDC…
UEG 2023
Neutrophil fibroblast crosstalk is driving fribrosis in…
UEG 2023
Morphologic alteration of mesentric lymph nodes under…
UEG 2023
Morphologische Veränderung mesenterialer Lymphknoten…
UEG 2023
Neutrophile Fibroblasteninteraktion treibt die Fibrose…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!